Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012;7(4):e34399.
doi: 10.1371/journal.pone.0034399. Epub 2012 Apr 3.

The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment

Tina S Skinner-Adams  1 , Alice S Butterworth, Kimberly A Porter, Ronald D'Amico, Fred Sawe, Doug Shaffer, Abraham Siika, Mina C Hosseinipour, Elizabeth Stringer, Judith S Currier, Tsungai Chipato, Robert Salata, Shahin Lockman, Joseph J Eron, Steven R Meshnick, James S McCarthy
Affiliations
Randomized Controlled Trial

The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment

Tina S Skinner-Adams et al. PLoS One. 2012.

Abstract

HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodium falciparum histidine-rich protein 2 antigen test, among 444 HIV-infected women initiating antiretroviral treatment (ART) in the OCTANE trial (A5208; ClinicalTrials.gov: NCT00089505). Participants were randomized to treatment with PI-containing vs. PI-sparing ART, and were followed prospectively for ≥48 weeks; 73% also received cotrimoxazole prophylaxis. PI-containing treatment was not associated with protection against malaria in this study population.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: RDS is employed by Abbot Pharmaceuticals, the funder of this study. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.

References

    1. Pisell TL, Hoffman IF, Jere CS, Ballard SB, Molyneux ME, et al. Immune activation and induction of HIV-1 replication within CD14 macrophages during acute Plasmodium falciparum malaria coinfection. Aids. 2002;16:1503–1509. - PubMed
    1. Whitworth JA, Hewitt KA. Effect of malaria on HIV-1 progression and transmission. Lancet. 2005;365:196–197. - PubMed
    1. Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis. 2008;198:948–961. - PubMed
    1. German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis. 2007;44:889–891. - PubMed
    1. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science. 2006;314:1603–1606. - PubMed

Publication types

Associated data